A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis

Genes and Development

Volumn 29, Issue 12, 2015, Pages 1271-1284

  Moroishi, Toshiro ^a   Park, Hyun Woo ^a   Qin, Baodong ^a,b   Chen, Qian ^c   Meng, Zhipeng ^a   Plouffe, Steven W ^a   Taniguchi, Koji ^a   Yu, Fa Xing ^d   Karin, Michael ^a   Pan, Duojia ^c   Guan, Kun Liang ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FUDAN UNIVERSITY   (China)

Author keywords

Cancer; Hippo pathway; Negative feedback; Phosphorylation; TAZ; YAP

Indexed keywords

CELL PROTEIN; CYCLOHEXIMIDE; HIPPO PROTEIN; LARGE TUMOR SUPPRESSOR 1 KINASE; LARGE TUMOR SUPPRESSOR 2 KINASE; LYSOPHOSPHATIDIC ACID; MERLIN; MESSENGER RNA; PHOSPHOTRANSFERASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR TEAD; TRANSCRIPTIONAL COACTIVATOR WITH PDZ BINDING MOTIF; UNCLASSIFIED DRUG; YES ASSOCIATED PROTEIN; DNA BINDING PROTEIN; HIPPO PROTEIN, MOUSE; LATS1 PROTEIN, MOUSE; LATS2 PROTEIN, MOUSE; PHOSPHOPROTEIN; PROTEIN SERINE THREONINE KINASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TAZ PROTEIN, MOUSE; TUMOR SUPPRESSOR PROTEIN; YAP PROTEIN, MOUSE;

ANIMAL TISSUE; ARTICLE; CELL DENSITY; CELL MIGRATION; CONTROLLED STUDY; CRISPR CAS SYSTEM; FEEDBACK SYSTEM; HUMAN; HUMAN CELL; MOLECULAR WEIGHT; MOUSE; NEGATIVE FEEDBACK; NONHUMAN; ORGAN SIZE; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN HOMEOSTASIS; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; SIGNAL TRANSDUCTION; ANIMAL; CELL CULTURE; CELL MOTION; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEK293 CELL LINE; HOMEOSTASIS; LIVER; MALE; METABOLISM; PHYSIOLOGY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL MOVEMENT; CELLS, CULTURED; DNA-BINDING PROTEINS; ENZYME ACTIVATION; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE EXPRESSION REGULATION; HEK293 CELLS; HOMEOSTASIS; HUMANS; LIVER; MALE; MICE; NEUROFIBROMIN 2; PHOSPHOPROTEINS; PROTEIN-SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 84933508767     PISSN: 08909369     EISSN: 15495477     Source Type: Journal    
DOI: 10.1101/gad.262816.115     Document Type: Article

References (47)

1. Adler JJ, Johnson DE, Heller BL, Bringman LR, RanahanWP, Conwell MD, Sun Y, Hudmon A,Wells CD. 2013. Serum deprivation inhibits the transcriptional co-activator YAP and cell growth via phosphorylation of the 130-kDa isoform of angiomotin by the LATS1/2 protein kinases. Proc Natl Acad Sci 110: 17368-17373.
2. Asthagiri AR, Parry DM, Butman JA, Kim HJ, Tsilou ET, Zhuang Z, Lonser RR. 2009. Neurofibromatosis type 2. Lancet 373: 1974-1986.
3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483: 603-607.
4. Barry ER, Camargo FD. 2013. The Hippo superhighway: signaling crossroads converging on the Hippo/Yap pathway in stem cells and development. Curr Opin Cell Biol 25: 247-253.
5. BossuytW, Chen CL, Chen Q, Sudol M, McNeill H, Pan D, Kopp A, Halder G. 2014. An evolutionary shift in the regulation of the Hippo pathway between mice and flies. Oncogene 33: 1218-1228.
6. Chan EH, Nousiainen M, Chalamalasetty RB, Schafer A, Nigg EA, Sillje HH. 2005. The Ste20-like kinase Mst2 activates the human large tumor suppressor kinase Lats1. Oncogene 24: 2076-2086.
7. Chan SW, Lim CJ, Guo K, Ng CP, Lee I, Hunziker W, Zeng Q, Hong W. 2008. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. Cancer Res 68: 2592-2598.
8. Chan SW, Lim CJ, Guo F, Tan I, Leung T, Hong W. 2013. Actinbinding and cell proliferation activities of angiomotin family members are regulated by Hippo pathway-mediated phosphorylation. J Biol Chem 288: 37296-37307.
9. Chen Q, Zhang N, Xie R, Wang W, Cai K-S, David KK, Huang B, Yabuta N, Nojima H, et al. 2015. Homeostatic control of Hippo signaling activity revealed by an endogenous activating mutation in YAP. Genes Dev (this issue). doi: 10. 1101/ gad. 264234. 115.
10. Cho E, Feng Y, Rauskolb C, Maitra S, Fehon R, Irvine KD. 2006. Delineation of a Fat tumor suppressor pathway. Nat Genet 38: 1142-1150.
11. Dai X, She P, Chi F, Feng Y, Liu H, Jin D, Zhao Y, Guo X, Jiang D, Guan KL, et al. 2013. Phosphorylation of angiomotin by Lats1/2 kinases inhibits F-actin binding, cell migration, and angiogenesis. J Biol Chem 288: 34041-34051.
12. Dong J, Feldmann G, Huang J, Wu S, Zhang N, Comerford SA, Gayyed MF, Anders RA, Maitra A, Pan D. 2007. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell 130: 1120-1133.
13. Dougherty MK, Muller J, Ritt DA, Zhou M, Zhou XZ, Copeland TD, Conrads TP, Veenstra TD, Lu KP, Morrison DK. 2005. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17: 215-224.
14. Enderle L, McNeill H. 2013. Hippo gains weight: added insights and complexity to pathway control. Sci Signal 6: re7.
15. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. 2010. Kibra is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell 18: 300-308.
16. Halder G, Dupont S, Piccolo S. 2012. Transduction of mechanical and cytoskeletal cues by YAP and TAZ. Nat Rev Mol Cell Biol 13: 591-600.
17. Hamaratoglu F, Willecke M, Kango-Singh M, Nolo R, Hyun E, Tao C, Jafar-Nejad H, Halder G. 2006. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 8: 27-36.
18. Harvey KF, Zhang X, Thomas DM. 2013. The Hippo pathway and human cancer. Nat Rev Cancer 13: 246-257.
19. Haskins JW, Nguyen DX, Stern DF. 2014. Neuregulin 1-activated ERBB4 interacts with YAP to induce Hippo pathway target genes and promote cell migration. Sci Signal 7: ra116.
20. Hergovich A. 2013. Regulation and functions of mammalian LATS/NDR kinases: looking beyond canonical Hippo signalling. Cell Biosci 3: 32.
21. Hirate Y, Hirahara S, Inoue K, Suzuki A, Alarcon VB, Akimoto K, Hirai T, Hara T, Adachi M, Chida K, et al. 2013. Polarity-dependent distribution of angiomotin localizes Hippo signaling in preimplantation embryos. Curr Biol 23: 1181-1194.
22. Johnson R, Halder G. 2014. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov 13: 63-79.
23. Jukam D, Xie B, Rister J, Terrell D, Charlton-Perkins M, Pistillo D, Gebelein B, Desplan C, Cook T. 2013. Opposite feedbacks in the Hippo pathway for growth control and neural fate. Science 342: 1238016.
24. Kim M, Kim M, Lee S, Kuninaka S, Saya H, Lee H, Lee S, Lim DS. 2013. cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes. EMBO J 32: 1543-1555.
25. Low BC, Pan CQ, Shivashankar GV, Bershadsky A, Sudol M, Sheetz M. 2014. YAP/TAZ as mechanosensors and mechanotransducers in regulating organ size and tumor growth. FEBS Lett 588: 2663-2670.
26. Mo JS, ParkHW, Guan KL. 2014. The Hippo signaling pathway in stem cell biology and cancer. EMBO Rep 15: 642-656.
27. Moroishi T, Hansen CG, Guan KL. 2015. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer 15: 73-79.
28. Murakami H, Mizuno T, Taniguchi T, Fujii M, Ishiguro F, Fukui T, Akatsuka S, Horio Y, Hida T, Kondo Y, et al. 2011. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res 71: 873-883.
29. Neto-Silva RM, de Beco S, Johnston LA. 2010. Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap. Dev Cell 19: 507-520.
30. Oh H, Irvine KD. 2010. Yorkie: the final destination of Hippo signaling. Trends Cell Biol 20: 410-417.
31. Pan D. 2010. The hippo signaling pathway in development and cancer. Dev Cell 19: 491-505.
32. Park HW, Guan KL. 2013. Regulation of the Hippo pathway and implications for anticancer drug development. Trends Pharmacol Sci 34: 581-589.
33. Piccolo S, Dupont S, Cordenonsi M. 2014. The biology of YAP/ TAZ: hippo signaling and beyond. Physiol Rev 94: 1287-1312.
34. Pierce KL, Premont RT, Lefkowitz RJ. 2002. Seven-transmembrane receptors. Nat Rev Mol Cell Biol 3: 639-650.
35. Plouffe SW, Hong AW, Guan KL. 2015. Disease implications of the Hippo/YAP pathway. Trends Mol Med 21: 212-222.
36. Ran FA, Hsu PD,Wright J, Agarwala V, Scott DA, Zhang F. 2013. Genome engineering using the CRISPR-Cas9 system. Nat Protoc 8: 2281-2308.
37. Sanjana NE, Shalem O, Zhang F. 2014. Improved vectors and genome-wide libraries for CRISPR screening. Nat Methods 11: 783-784.
38. Taniguchi K, Wu LW, Grivennikov SI, de Jong PR, Lian I, Yu FX, Wang K, Ho SB, Boland BS, Chang JT, et al. 2015. Agp130-Src-YAP module links inflammation to epithelial regeneration. Nature 519: 57-62.
39. Thompson BJ, Pichaud F, Roper K. 2013. Sticking together the Crumbs-an unexpected function for an old friend. Nat Rev Mol Cell Biol 14: 307-314.
40. Varelas X. 2014. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development 141: 1614-1626.
41. Wackerhage H, Del Re DP, Judson RN, Sudol M, Sadoshima J. 2014. The Hippo signal transduction network in skeletal and cardiac muscle. Sci Signal 7: re4.
42. Yin F, Yu J, Zheng Y, Chen Q, Zhang N, Pan D. 2013. Spatial organization of Hippo signaling at the plasma membrane mediated by the tumor suppressor Merlin/NF2. Cell 154: 1342-1355.
43. Yu FX, Zhao B, Panupinthu N, Jewell JL, Lian I,Wang LH, Zhao J, Yuan H, Tumaneng K, Li H, et al. 2012. Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 150: 780-791.
44. Zhang N, Bai H, David KK, Dong J, Zheng Y, Cai J, Giovannini M, Liu P, Anders RA, Pan D. 2010. The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 19: 27-38.
45. Zhao B, Ye X, Yu J, Li L, LiW, Li S, Yu J, Lin JD, Wang CY, Chinnaiyan AM, et al. 2008. TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22: 1962-1971.
46. Zhao B, Li L, Tumaneng K, Wang CY, Guan KL. 2010. A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(β-TRCP). Genes Dev 24: 72-85.
47. Zhao B, Li L, Lu Q, Wang LH, Liu CY, Lei Q, Guan KL. 2011. Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein. Genes Dev 25: 51-63.